According to research report the dPCR and qPCR market is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period.
Factors such as the growth in the geriatric population, rising incidence of infectious diseases and genetic disorders, technological advancements in the field of PCR, and increasing investments and availability of funds for PCR-based research are driving the growth of the global dPCR and qPCR market.
Product Launches: Key Strategy Adopted by the Major Players in this dPCR and qPCR Market
New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global dPCR and qPCR market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global dPCR and qPCR market.
The dPCR technology segment is expected to grow at a faster rate than qPCR in coming years
On the basis of technology, the global dPCR and qPCR market is segmented into quantitative PCR (qPCR) and digital PCR (dPCR) technologies. Among the two categories, qPCR segment accounted for larger share of global dPCR and qPCR market in 2017.
However, the dPCR segment is growing at faster rate during the forecast period. This is mainly attributed to ongoing technological developments in the field, significant adoption rate of dPCR products among key end users (as compared to qPCR and other PCR products) across mature markets, continued expansion in distribution networks of emerging dPCR product manufacturers, and growing private funding to develop and commercialize innovative dPCR instruments.
The key players in the dPCR and qPCR market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Promega Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience, Inc. (US), and Analytik Jena AG (Germany), among others.
